The top medtech stories of early 2017

Share
Omnipod Insulet diabetes

[Image courtesy of Insulet]

Diabetes treatment advances

There was also positive news on the diabetes device front.

Insulet said the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system showed the automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe for use by people with type 1 diabetes. Production is expected to start at a new Acton, Mass. plant in 2019.

DexCom meanwhile announced that CMS has classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company said the Dexcom G5 Mobile is the only continuous glucose monitor to that falls under the classification, with the Medicare coverage giving DexCom a potential competitive advantage.

DeviceTalks West: Expertise you need to know

textadimage Medical device suppliers are light years away from the days when they merely filled orders to spec for medtech OEMs – as a visit to the upcoming DeviceTalks West will quickly confirm.

From incorporating steerability into catheters to getting validation and testing done right, the companies serving the medical device industry have become specialized experts in their own right.

Read on to discover five example of medical device expertise to be had at DeviceTalks West, which runs Dec. 11–12 in Orange County, Calif.

Pages: 1 2 3 4 5 6

Speak Your Mind

*